Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form
in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients
receive transfusions of plasma, the liquid part of blood, from healthy donors. This study
will examine the effectiveness of an antibody, rituximab, in combination with plasma
exchange, at improving the immune response in people with TTP and decreasing the recurrence
of TTP.
Phase:
Phase 3
Details
Lead Sponsor:
HealthCore-NERI New England Research Institutes
Collaborators:
Genentech, Inc. National Heart, Lung, and Blood Institute (NHLBI)